The molecular mystery behind vaccine-induced immune thrombocytopenia and thrombosis (VITT) has been solved, revealing how a specific adenoviral protein triggers dangerous blood clots through evolutionary molecular mimicry. This breakthrough explains why some individuals develop life-threatening clotting disorders after COVID-19 adenoviral vaccines or natural adenovirus infections.
Researchers identified adenoviral core protein VII (pVII) as the precise trigger that initiates VITT. Through sophisticated antibody proteomics analysis of 121 patients, they discovered that anti-VITT antibodies share a critical genetic signature: the IGLV3-21 light-chain allele with a specific K31E mutation. Only antibodies targeting pVII—not intact virions or other adenoviral proteins—contained species that cross-react with platelet factor 4 (PF4), the protein responsible for dangerous platelet activation. The cross-reactivity maps to a basic linear epitope on pVII that molecularly mimics PF4.
This finding represents a significant advance in understanding autoimmune complications following vaccination. The identification of pVII as the inciting antigen provides a mechanistic explanation for VITT's rarity—it requires both exposure to this specific viral protein and the presence of particular genetic variants that enable molecular mimicry. The research validates concerns about adenoviral vectors while offering pathways for safer vaccine design. For the rare individuals carrying susceptible genetic variants, this knowledge could inform personalized vaccination strategies and enable earlier recognition of VITT risk factors. The work also demonstrates how evolutionary pressures can create dangerous molecular coincidences between pathogens and human proteins.